<DOC>
	<DOCNO>NCT02661178</DOCNO>
	<brief_summary>This study investigate safety , tolerability , pharmacokinetics single ascend dos emodepside ( BAY 44-4400 ) healthy male volunteer . This study also conduct exploratory investigation relative bioavailability emodepside administer tablet .</brief_summary>
	<brief_title>First Man Clinical Trial Emodepside ( BAY 44-4400 )</brief_title>
	<detailed_description />
	<criteria>Male , Caucasian volunteer , deem healthy basis clinical history , physical examination , ECG , vital sign , laboratory test blood urine . Optionally , evaluation study , sponsor 's discretion ethnic group may recruit . Aged 18 55 year . With body mass index ( BMI ; Quetelet index ) range 18 30.1 kg/m2 screening . Sufficient intelligence understand nature trial hazard participate . Ability communicate satisfactorily investigator participate , comply requirement , entire trial . Willingness give write consent participate , read information consent form , opportunity discuss trial investigator delegate Participation another clinical trial within 3 month prior study , 5times halflife drug test previous clinical trial , whichever long ( time calculate relative last dose previous clinical trial ) Clinically relevant abnormal medical history , concurrent medical condition , acute chronic illness history chronic illness sufficient invalidate subject 's participation trial make unnecessarily hazardous . Surgery ( eg stomach bypass ) medical condition might affect absorption study drug take orally . Presence abnormal physical finding , ECG , laboratory value pretrial screening assessment could interfere objective trial safety subject . Positive test hepatitis B &amp; C , HIV Presence history drug alcohol abuse last 10 year , intake 21 unit alcohol weekly . Regular daily consumption one liter xanthinecontaining beverage Regular daily consumption 5 cigarette daily , use 3 gram ( 1/8 ounce ) tobacco Use prescription medicine 28 day first dose trial medication use overthecounter medicine , exception acetaminophen ( paracetamol ) , 7 day first dose trial medication Use dietary supplement herbal remedy ( St John 's Wort ) know interfere CYP3A4 and/or Pgp metabolic pathways 28 day first dose trial medication ( see list Study Procedures Manual )</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Parasitic Diseases</keyword>
	<keyword>Helminthiasis</keyword>
	<keyword>Nematode Infections</keyword>
	<keyword>Secernentea Infections</keyword>
	<keyword>Spirurida Infections</keyword>
	<keyword>Filariasis</keyword>
	<keyword>Skin Diseases , Parasitic</keyword>
	<keyword>Skin Connective Tissue Diseases</keyword>
	<keyword>Skin Diseases</keyword>
	<keyword>Skin Diseases , Infectious</keyword>
	<keyword>Depsipeptides</keyword>
	<keyword>Emodepside</keyword>
	<keyword>Neglected disease</keyword>
	<keyword>Africa</keyword>
	<keyword>New drug</keyword>
	<keyword>Oral drug</keyword>
	<keyword>Parasite</keyword>
	<keyword>Anthelmintic drug</keyword>
	<keyword>Cyclooctadepsipeptide</keyword>
	<keyword>Single ascend dose</keyword>
	<keyword>Volunteers</keyword>
	<keyword>Phase 1</keyword>
	<keyword>Safety</keyword>
	<keyword>Tolerability</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Relative bioavailability</keyword>
	<keyword>Onchocerciasis</keyword>
</DOC>